ID   HNT-34
AC   CVCL_2071
SY   HNT34
DR   CLO; CLO_0050982
DR   EFO; EFO_0006583
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN01821631
DR   BioSample; SAMN03472915
DR   BioSample; SAMN10989583
DR   CCLE; HNT34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01621
DR   Cosmic; 787435
DR   Cosmic; 975253
DR   Cosmic; 1012069
DR   Cosmic; 1281316
DR   Cosmic; 2306209
DR   Cosmic; 2378086
DR   DepMap; ACH-000299
DR   DSMZ; ACC-600
DR   GEO; GSM1446757
DR   PharmacoDB; HNT34_558_2019
DR   RCB; RCB1296
DR   Wikidata; Q54890075
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9266939;
RX   PubMed=10637496;
RX   PubMed=16408098;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Population: Japanese.
CC   Doubling time: 26-27 hours (PubMed=9266939); 34 hours (PubMed=25984343); ~40 hours (DSMZ).
CC   Sequence variation: Gene fusion; BCR-ABL1 (PubMed=25485619; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.86%; Native American=0%; East Asian, North=80.82%; East Asian, South=13.41%; South Asian=0%; European, North=0%; European, South=3.91% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): DSMZ; PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 10,11
ST   D16S539: 9,12
ST   D18S51: 13,16
ST   D21S11: 28,32.2
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 20,26
ST   Penta D: 10
ST   Penta E: 11,14
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 14
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 26
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9266939; DOI=10.1046/j.1365-2141.1997.2143029.x;
RA   Hamaguchi H., Suzukawa K., Nagata K., Yamamoto K., Yagasaki F.,
RA   Morishita K.;
RT   "Establishment of a novel human myeloid leukaemia cell line (HNT-34)
RT   with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1
RT   gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with
RT   AML after MDS with 3q21q26 syndrome.";
RL   Br. J. Haematol. 98:399-407(1997).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//